This technology features ginsenoside MC1, a low-molecular-weight metabolite produced when protopanaxadiol-type ginsenosides in ginseng lose their sugar moieties, as an active ingredient for anti-inflammatory pharmaceutical and food compositions. MC1 effectively suppresses inflammatory responses within vascular cells.
While inflammation is a defensive response to eliminate pathogens and regenerate tissue, excessive or prolonged inflammation causes mucosal damage and tissue destruction, leading to chronic conditions such as arthritis, inflammatory bowel disease, and inflammatory skin diseases. Conventional treatments like antihistamines and corticosteroids often provide only temporary relief and carry significant side effects, creating a need for new anti-inflammatory agents.
This technology utilizes ginsenoside MC1, which can be isolated from various ginseng extracts—such as fresh, red, or white ginseng—or obtained through synthesis or commercial sources, and is formulated for both pharmaceutical and daily dietary use. Its key feature is the direct use of a metabolite with a smaller molecular structure than major ginsenosides. It can be applied as a candidate for chronic inflammatory treatments like arthritis and dermatitis, as well as in functional red ginseng foods for vascular health and anti-inflammatory topical agents, enabling the development of high-value ginseng products that serve as alternatives to steroid-based drugs.
N/A
